However, the clinical outcomes remain mostly unsatisfactory and are sometimes affected by treatment-related adverse events.<h4>Case presentation</h4>A 57-year-old woman with ES-SCLC was administered a combination therapy of atezolizumab (a PD-L1 inhibitor) and anlotinib [an oral multi-targeted tyrosine kinase inhibitor (TKI)]. This evidence concerns the gene CD274 and small cell lung carcinoma.